DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Gilteritinib |
DMTI0ZO
|
Moderate |
Decreased clearance of Ulipristal due to the transporter inhibition by Gilteritinib. |
Acute myeloid leukaemia [2A60]
|
[5] |
Troleandomycin |
DMUZNIG
|
Minor |
Decreased metabolism of Ulipristal caused by Troleandomycin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[5] |
Pexidartinib |
DMS2J0Z
|
Moderate |
Increased metabolism of Ulipristal caused by Pexidartinib mediated induction of CYP450 enzyme. |
Bone/articular cartilage neoplasm [2F7B]
|
[6] |
Talazoparib |
DM1KS78
|
Moderate |
Decreased clearance of Ulipristal due to the transporter inhibition by Talazoparib. |
Breast cancer [2C60-2C6Y]
|
[7] |
Tucatinib |
DMBESUA
|
Moderate |
Decreased metabolism of Ulipristal caused by Tucatinib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[8] |
Fidaxomicin |
DMFP6MV
|
Minor |
Decreased clearance of Ulipristal due to the transporter inhibition by Fidaxomicin. |
Clostridium difficile enterocolitis [1A04]
|
[9] |
Ripretinib |
DM958QB
|
Moderate |
Decreased clearance of Ulipristal due to the transporter inhibition by Ripretinib. |
Gastrointestinal stromal tumour [2B5B]
|
[9] |
Aliskiren |
DM1BV7W
|
Moderate |
Decreased clearance of Ulipristal due to the transporter inhibition by Aliskiren. |
Hypertension [BA00-BA04]
|
[10] |
Berotralstat |
DMWA2DZ
|
Major |
Decreased clearance of Ulipristal due to the transporter inhibition by Berotralstat. |
Innate/adaptive immunodeficiency [4A00]
|
[11] |
Naloxegol |
DML0B41
|
Minor |
Decreased clearance of Ulipristal due to the transporter inhibition by Naloxegol. |
Large intestine motility disorder [DB32]
|
[12] |
PF-06463922 |
DMKM7EW
|
Moderate |
Increased metabolism of Ulipristal caused by PF-06463922 mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[13] |
Selpercatinib |
DMZR15V
|
Moderate |
Decreased metabolism of Ulipristal caused by Selpercatinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[5] |
GDC-0199 |
DMH0QKA
|
Major |
Decreased clearance of Ulipristal due to the transporter inhibition by GDC-0199. |
Mature B-cell leukaemia [2A82]
|
[9] |
IPI-145 |
DMWA24P
|
Moderate |
Decreased metabolism of Ulipristal caused by IPI-145 mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[5] |
Arry-162 |
DM1P6FR
|
Moderate |
Decreased clearance of Ulipristal due to the transporter inhibition by Arry-162. |
Melanoma [2C30]
|
[9] |
Ubrogepant |
DM749I3
|
Moderate |
Decreased clearance of Ulipristal due to the transporter inhibition by Ubrogepant. |
Migraine [8A80]
|
[14] |
Rucaparib |
DM9PVX8
|
Moderate |
Decreased metabolism of Ulipristal caused by Rucaparib mediated inhibition of CYP450 enzyme. |
Ovarian cancer [2C73]
|
[15] |
Abametapir |
DM2RX0I
|
Moderate |
Decreased metabolism of Ulipristal caused by Abametapir mediated inhibition of CYP450 enzyme. |
Pediculosis [1G00]
|
[16] |
Lefamulin |
DME6G97
|
Moderate |
Decreased metabolism of Ulipristal caused by Lefamulin mediated inhibition of CYP450 enzyme. |
Pneumonia [CA40]
|
[5] |
Riociguat |
DMXBLMP
|
Moderate |
Decreased clearance of Ulipristal due to the transporter inhibition by Riociguat. |
Pulmonary hypertension [BB01]
|
[9] |
Telotristat ethyl |
DMDIYFZ
|
Moderate |
Increased metabolism of Ulipristal caused by Telotristat ethyl mediated induction of CYP450 enzyme. |
Small intestine developmental anomaly [DA90]
|
[5] |
LEE011 |
DMMX75K
|
Moderate |
Decreased metabolism of Ulipristal caused by LEE011 mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[17] |
Fostamatinib |
DM6AUHV
|
Moderate |
Decreased metabolism of Ulipristal caused by Fostamatinib mediated inhibition of CYP450 enzyme. |
Thrombocytopenia [3B64]
|
[18] |
----------- |
|
|
|
|
|